PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 20260 citations

Methyltransferase 3 promotes v-set and transmembrane domain-containing 2-like protein expression to intensify ferroptosis-mediated prostate adenocarcinoma progression through the m6A methylation modification.

View Full Paper
JLJinming LiJJJun JiangSWShaoxing Wang

Key Points

  • The study aims to investigate the role of METTL3 in regulating VSTM2L expression and its effects on ferroptosis in prostate adenocarcinoma.
  • Examined the expression levels of METTL3 and VSTM2L in prostate adenocarcinoma tissues.
  • Analyzed the effects of METTL3 on ferroptosis via m6A methylation modification.
  • Utilized RNA interference techniques to assess the impact of VSTM2L on cell survival.
  • Found that METTL3 stabilizes VSTM2L expression in prostate adenocarcinoma.
  • Demonstrated that enhanced VSTM2L levels inhibit ferroptosis, promoting cancer progression.
  • Established the METTL3/VSTM2L axis as a novel target for cancer therapy.

Abstract

METTL3 promotes PRAD progression by stabilizing VSTM2L expression through m6A methylation, thereby inhibiting ferroptosis. This study establishes a direct link between RNA methylation and ferroptosis in PRAD, revealing the METTL3/VSTM2L axis as a novel regulatory pathway and a potential therapeutic target.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e505a333a821460c8cehttps://doi.org/10.14670/hh-25-070
Ask AI
Helpful
Bookmark
Share
View Full Paper